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Objective: This study aims to evaluate the operative efﬁcacy and safety of the GreenLight 180-W XPS
laser system in comparison to the GreenLight 120-W HPS system used by a single experienced surgeon
for the treatment of bladder outlet obstruction caused by an enlarged prostate.
Materials and methods: We retrospectively compared the patients undergoing GreenLight 180-W XPS
(September 2014eSeptember 2015) and GreenLight 120-W HPS (August 2008eSeptember 2009) for
lower urinary tract symptoms secondary to benign prostatic hyperplasia by a single experienced surgeon.
The patient baseline characteristics, perioperative parameters, and complications were recorded. Pros-
tate size and prostate-speciﬁc antigen were also assessed. Functional parameters, including International
Prostate Symptom Score, maximum uroﬂow rate, postvoid residual, and quality of life score, were
analyzed in different follow-up periods.
Results: A total of 130 patients (65 in the HPS and 65 in the XPS group) were included in this study.
Intraoperative lasing time was signiﬁcantly shorter in the XPS group, but the postoperative length of
catheterization and hospital stay were comparable in both groups. The number of ﬁbers used during
vaporization was signiﬁcantly less, and only one case required two ﬁbers for prostate vaporization in the
XPS group (p¼ 0.03). During the follow-up period, there was statistically signiﬁcant improvement
compared with baseline in all functional parameters in each group. However, no signiﬁcant difference
was observed in these parameters between the two groups. The mean percentages of prostate volume
reduction were 57% and 41% and those of prostate-speciﬁc antigen reduction were 60% and 49%,
respectively, in the XPS and HPS groups. Complications were comparable between the two groups.
Conclusion: The 180-W XPS system displays a shorter lasing time, less laser ﬁber use, more volume
reduction, and a comparable safety proﬁle in comparison with the 120-W HPS system for the treatment
of bladder outlet obstruction caused by an enlarged prostate.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Benign prostatic hyperplasia (BPH) is a common disease in aging
males. Bothersome lower urinary tract symptoms secondary to BPH
have a negative impact on patients’ quality of life. Transurethral
resection of the prostate (TURP) has been the reference surgical
treatment for BPH over the past few decades. In spite of its good
efﬁcacy and tissue removal, TURP may sometimes be associated
with complications, especially in patients with large prostates or
those on anticoagulants.1,2 To overcome the drawbacks, photo-
selective vaporization of the prostate has been developing rapidlyKaohsiung Chang Gung Me-
g, Taiwan.
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urologist, Urological Sciencein the past decade. GreenLight laser prostatectomy is a user-
friendly procedure and has been used worldwide for BPH treat-
ment.3,4 The ablative ability remains questionable, resulting in an
advancement in power setting from an initial 80- to a 120-W HPS
system. Many studies have reported the efﬁcacy and safety of the
120-W HPS system in the treatment of BPH.5e10 However, a
retreatment rate of 11% in prostates with a size of > 80 mL was
reported by Al-Ansari et al6 at the follow-up of 36 months. Another
study by Tas¸çı et al11 also showed a high retreatment rate of 16% in
prostates with a size > 70 mL due to recurrent adenoma.
The latest version of GreenLight laser (180-W XPS system, AMS,
Minnetonka, MI) has been developed with the aim to improve
vaporization efﬁciency, especially in large prostates. This device has
been introduced in our hospital in 2014. The GreenLight XPS laseriwan LLC. This is an open access article under the CC BY-NC-ND license (http://
0-W XPS laser versus 120-W HPS laser for the treatment of benign
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Table 1
Patient baseline and perioperative parameters.
Parameter XPS HPS p
No. of patients 65 65
Age (y) 70.8± 8.4 69.4± 8.2 0.32
ASA score 2.3± 0.6 2.1± 0.6 0.07
Prostate vol. (mL) 61.2± 27.0 60.4± 22.0 0.86
Lasing time (min) 26.8± 14.4 34.3± 11.8 0.002
Catheterization time (h) 19.1± 13.3 22.9± 20.9 0.23
Hospital stay (d) 1.7± 1.3 2.0± 1.6 0.23
Applied energy (KJ) 210.9± 126.6 211.9± 76.9 0.96
No. of ﬁbers used 0.03
1 64 57
2 1 8
Data are presented as n or mean± standard deviation, unless otherwise indicated.
ASA¼American Society of Anesthesiologists.
Table 2
Clinical outcomes at baseline, 1e6 months, and 7e12 months after surgery.
Parameter Baseline 1e6 mo 7e12 mo
IPSS
XPS 17.8± 5.1 (n¼ 65) 4.5± 2.5 (n¼ 31) 4.0± 2.1 (n¼ 16)
HPS 18.8± 2.8 (n¼ 65) 4.6± 1.9 (n¼ 46) 5.1± 1.9 (n¼ 21)
Qmax (mL/s)
XPS 6.9± 5.3 (n¼ 41) 19.2± 8.7 (n¼ 13) 19.4± 11.1 (n¼ 13)
HPS 5.5± 6.0 (n¼ 49) 18.3± 7.7 (n¼ 39) 16.5± 7.9 (n¼ 14)
PVR (mL)
XPS 146.4± 160.7 (n¼ 36) 25.5± 17.6 (n¼ 17) 30.4± 34.7 (n¼ 13)
HPS 141.3± 82.1 (n¼ 38) 36.6± 33.5 (n¼ 31) 37.8± 35.1 (n¼ 8)
QoLs
XPS 4.0± 0.8 (n¼ 65) 2.2± 1.0 (n¼ 23) 1.5± 1.3 (n¼ 13)
HPS 4.2± 0.8 (n¼ 65) 1.8± 0.7 (n¼ 37) 1.8± 1.1 (n¼ 17)
Data are expressed as mean± standard deviation.
IPSS¼ International Prostate Symptom Score; n¼ number of available data;
PVR¼ postvoid residual; Qmax¼maximum uroﬂow rate; QoLs¼ quality of life
score.
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emits maximum power up to 180 W as well as a 50% increase in
laser beam area by usingMoXy ﬁber. In addition to increased power
setting, there are some improvements including active cooling cap
technology and temperature sensing system (FiberLife), aiming at
preventing overheating and increasing ﬁber longevity. Another
improvement is the pulsed coagulation feature (TruCoagdpulse
modulated at 12 Hz 25% duty cycle, 5e40 W), which is claimed to
provide better hemostasis.12,13
The purpose of this study was to evaluate the operative efﬁcacy
and safety of the GreenLight 180-WXPS laser system in comparison
to the GreenLight 120-W HPS system used by a single experienced
surgeon for the treatment of BPH.
2. Materials and methods
2.1. Study population
This study was reviewed and approved by the Institutional Re-
view Board of our hospital (No. 201600311B0). Data were retro-
spectively collected from patients with lower urinary tract
symptoms secondary to BPH undergoing treatment with the
GreenLight 120-W HPS system (August 2008eSeptember 2009) or
180-W XPS system (September 2014eSeptember 2015) by a single
surgeon (P.-H.C.). P.-H.C. has extensive experience in GreenLight
laser prostatectomy. All the patients included in this study showed
a poor response to a-blocker or 5a-reductase inhibitor. Indications
for surgery were based on the European Association of Urology
guideline or the American Urological Association guideline on BPH
treatment.14,15 Before surgery, prostatic biopsy might be performed
if abnormal serum prostate-speciﬁc antigen (PSA) level or ﬁnding
from digital rectal examination. The exclusion criteria for analysis
were prior urethral surgery, suspected neurogenic bladder, and
prostate cancer.
2.2. Surgical technique
The surgical procedures were similar between the HPS and XPS
systems, as described in our previous article.7 Brieﬂy, these tech-
niques were performed under spinal or general anesthesia. Normal
saline was used as the irrigation ﬂuid. The lateral lobes were
vaporized bilaterally at ﬁrst using 80Wof power. After the working
space was created, the power settings were increased up to 120 W
(HPS system) or 180 W (XPS system) to vaporize prostatic tissue. If
encountering bleeders, the power was set to 20e30 W for coagu-
lation. The end point of both techniques was to create a TURP-like
cavity without obstructing tissue protruding into the prostatic fossa
after emptying the bladder. At the end of procedure, a 20F or 22F
Foley catheter was placed without traction in most cases. If there
was no signiﬁcant hematuria, the Foley catheter was removed the
next morning for voiding trial.
2.3. Assessment
The primary outcomes were intraoperative lasing time and
postoperative prostate volume change. Various secondary out-
comes, including International Prostate Symptom Score, maximum
uroﬂow rate, postvoid residual, quality of life score, number of used
ﬁbers, and complications,were assessed. Prostate sizewas evaluated
before and after surgery by transrectal ultrasound. Peri- and post-
operative complicationswere also recorded. To evaluate the prostate
volume reduction and PSA change, only patients with both pre- and
postoperative data on prostate volume or PSA value were analyzed.
The comparison of volume reduction percentage and PSA change
between the two groups was performed using t test. Subjective andPlease cite this article in press as: Chen C-H, Chiang P-H, GreenLight 18
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Score, maximum uroﬂow rate, postvoid residual, and quality of life
score) were analyzed in different follow-up periods.
2.4. Statistical analyses
Results were given as mean± standard deviation or number of
patients (percentage). The paired t test was used to compare the
data in the same group before and after surgery. Quantitative var-
iables between the two groups were compared using the Student t
test. Fisher’s exact test was used for the analysis of categorical data.
Statistical analysis was performed using the SPSS Statistics version
17.0 software (SPSS Inc., Chicago, IL, USA) package. A two-sided p
value < 0.05 was considered statistically signiﬁcant.
3. Results
A total of 130 patients (65 in the HPS and 65 in the XPS group)
met the criteria and were included in this study. The patient
characteristics and perioperative parameters between the two
groups are shown in Table 1. There was no signiﬁcant difference in
preoperative patient characteristics. Intraoperative lasing time was
signiﬁcantly shorter in the XPS group, but the postoperative length
of catheterization and hospital stay were comparable in both
groups. The number of ﬁbers used during vaporization was signif-
icantly less and only one case required two ﬁbers for prostate
vaporization in the XPS group (p¼ 0.03). During the follow-up
period, there was statistically signiﬁcant improvement compared
with baseline in all functional parameters (International Prostate
Symptom Score, postvoid residual, maximum uroﬂow rate, and0-W XPS laser versus 120-W HPS laser for the treatment of benign
e (2016), http://dx.doi.org/10.1016/j.urols.2016.07.003
Table 3
Prostate volume and PSA change after surgery.
Parameter XPS HPS p
Preop volume 60.2± 25.8 (n¼ 23)a 61.7± 21.6 (n¼ 38)a 0.79
Postop volume 25.9± 9.7 (n¼ 23)a 36.5± 10.8 (n¼ 38)a 0.0003
Volume reduction (%) 57 (31e85) 41 (16e74) 0.0008
Preop PSA 5.59± 4.07 (n¼ 21)a 8.34± 6.46 (n¼ 21)a 0.106
Postop PSA 2.25± 1.73 (n¼ 21)a 4.23± 3.3 (n¼ 21)a 0.019
PSA reduction (%) 60 (12e96) 49 (12e79) 0.14
Data are presented as n (range) or mean± standard deviation, unless otherwise
indicated.
Postop¼ postoperative; Preop¼ preoperative; PSA¼ prostate-speciﬁc antigen.
a Only patients with both preop and postop data on prostate volume or PSA value
were analyzed.
Table 4
Peri- and postoperative complications.
XPS (65) HPS (65) p
Blood transfusion 0 0 >0.99
TUR syndrome 0 0 >0.99
Temporary recatheterization 7 (11) 14 (22) 0.152
Urge incontinence 3 (5) 2 (3) 0.99
Stress incontinence 1 (2) 0 0.99
Dysuria 15 (23) 21 (32) 0.327
UTI 1 (2) 1 (2) >0.99
Hematuria requiring surgery 1 (2) 1 (2) >0.99
Redo TURP/PVP 0 1 (1.5) 0.99
Urethral stricture 1 (2) 1 (2) >0.99
Data are presented as n (%).
TUR¼ transurethral resection; TURP/PVP¼ transurethral resection of the prostate/
photoselective vaporization of the prostate; UTI¼ urinary tract infection.
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ence was observed in these parameters between the two groups
(Table 2). The percentages of prostate volume reduction were 57%
and 41%, and those of PSA reduction were 60% and 49%, respec-
tively, in the XPS and HPS groups (Table 3). With regard to surgical
complications (Table 4), no one needed blood transfusion in both
groups. Recatheterization was deﬁned as urinary retention
requiring Foley catheter indwelling within 7 days after surgery. The
recatheterization rate was lower in the XPS group, but there was no
statistically signiﬁcant difference. The rate of temporary urge in-
continence was low in both groups, and most cases got relief with
antimuscarinics at the outpatient clinic. Dysuria, deﬁned as
micturition pain or burning sensation on urination, was the most
common complaint after surgery in both groups (23% vs. 32%,
p¼ 0.327). Most cases with dysuria were treated with painkillers or
oral antibiotics for pyuria. In addition to dysuria, hematuria was
also common in both groups. Most hematuria events weremild and
could bemanaged successfully with conservative treatment such as
hydration or medication. Only two patients (1 in the XPS and 1 in
the HPS group) had large blood clot retention and required endo-
scopic intervention. At 12-month follow-up, no one required redo
TURP or photoselective vaporization of the prostate for residual
prostatic tissue or regrowth of prostatic tissue in the XPS group, but
one case (prostate size: 80 mL) in the HPS group.
4. Discussion
Although the 120-W HPS system using a lithium triborate
crystal provides higher power setting compared with the previous
GreenLight 80-W potassium-titanyl-phosphate laser system, the
ablative efﬁcacy on large prostates remains a big challenge due to
higher retreatment rates compared with TURP.6 A meta-analysis
study has suggested that GreenLight photoselective vaporization
of the prostate is suitable for patients with a prostate size of <Please cite this article in press as: Chen C-H, Chiang P-H, GreenLight 18
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enucleation of the prostate, provides comparable outcomes with
TURP and open prostatectomy. Although holmium laser enucle-
ation of the prostate is a reliable option in large prostates,16e18 the
tough learning curve limits its worldwide use.19
To overcome the drawback of the 120-W HPS system, the latest
generation of the GreenLight XPS system usingMoXy ﬁber provides
maximum power output up to 180 W and a 50% increase in laser
beam area from 0.28 mm2 to 0.44 mm2. In an animal model, Malek
et al13 have shown that 180-W XPS laser could create a 76% larger
cavity and vaporize tissue at a 77% higher rate compared with 120-
W HPS laser. From our preliminary study, the new-generation 180-
W XPS system displays less lasing time, but a larger prostate vol-
ume reduction without compromising the safety proﬁle in com-
parison with the 120-W HPS system. The results reﬂect the
improved ablative capacity of the 180-W XPS system.
Several clinical reports have also shown the promising results of
the 180-W XPS system. Bachmann et al20 ﬁrst reported the good
functional outcomes of 201 patients undergoing treatmentwith the
180-W XPS system, with a mean follow-up of 5.8 months, at seven
centers worldwide. In their series, PSA fell by 53% after 3 months
and by 63% after 6 months. The prostate volume reduction reached
51% in patients with a prostate size of > 80 mL. These results are
similar to our ﬁndings. In comparison with previous HPS laser, a
signiﬁcant PSA reduction (79% vs. 54% at 6 months), as well as an
approximately 50% reduction on operating and laser time, has been
observed by Ben-Zvi et al21 in case of XPS laser. Hueber et al22 also
found comparable results in a large-scale multicenter study. Even
in a large prostate (> 80 mL), XPS laser prostatectomy is still a safe
procedure and no one required reintervention due to residual ad-
enoma at 12-month follow-up.23 To date, there is limited literature
on the comparison between the 180-W XPS system and conven-
tional TURP. A prospective multicenter randomized study
comparing photoselective vaporization of the prostate with the
GreenLight XPS™ laser system and transurethral resection of the
prostate for the treatment of benign prostatic hyperplasia (The
Goliath Study) is the largest trial conducted to evaluate the non-
inferiority of the 180-W XPS system to TURP in terms of subjective
and objective parameters as well as surgical complications.24,25
This study demonstrated that the functional outcomes were com-
parable between the two techniques. However, time to stable
health status, catheterization time, and length of hospital stay were
in favor of the XPS system. Postoperative retreatment was more
common after TURP within the ﬁrst 30 days (9.8% vs. 2.9%;
p¼ 0.025), but comparable with XPS at 12-month follow-up (15.0%
vs. 11.8%).
With regard to peri- and postoperative complications, the XPS
system displays a similar safety proﬁle to the HPS system. In an
animal model, 180-W XPS revealed a 33% thicker coagulation zone
than 120-W HPS in the vaporization of the dog prostate
(2.0± 0.4 mm vs. 1.5± 0.3 mm, p< 0.005),13 and this ﬁnding may
raise the question that whether XPS would result in more irritative
symptoms after surgery due to deeper coagulative necrosis, as seen
in diode laser prostatectomy.7,26 However, in the current series, the
proportions of postoperative urinary incontinence in the two groups
were similar. These urinary incontinence events were temporary,
and most of them were treated with antimuscarinics. In Bachmann
et al's20 study, theTURP loopwas required to control bleeding in 3.5%
(7/201) of procedures, which was signiﬁcantly associated with
capsule perforation. In case of large prostates (> 80 mL) treated by
XPS, Altay el al23 reported that the TURP loop was used in 7.3% of
patients due to uncontrolled bleeding. Although there was no deﬁ-
nite record of intraoperative capsular perforation in the current
study, no one needed the use of TURP loop due to uncontrolled
bleeding in the XPS group. Thismay be explained by the lowermean0-W XPS laser versus 120-W HPS laser for the treatment of benign
(2016), http://dx.doi.org/10.1016/j.urols.2016.07.003
C.-H. Chen, P.-H. Chiang / Urological Science xxx (2016) 1e44prostate volume in our series, and P.-H.C.’s 12-year experience with
previous potassium-titanyl-phosphate, HPS, and XPS.
At 12-month follow-up, the proportion of retreatment due to
residual adenoma or regrowth of adenoma was lower in the XPS
group, although there was no statistically signiﬁcant difference.
This ﬁnding might be reﬂected by more volume reduction in the
XPS group than in the HPS group (57% vs. 41%). In addition to
increased power output and laser beam area in the XPS system, the
new characteristics of MoXy ﬁber also play an important role in
improving ablative efﬁcacy and more volume reduction. In former
120-W HPS laser prostatectomy, prostatic tissue becomes more
desiccated as vaporization proceeds. In addition to tissue desicca-
tion, the destruction or melting of laser ﬁber tip may reduce light
transmission and power density on the working surface, resulting
in reduced ablative efﬁcacy. An improvement in the 180-W XPS
system is the MoXy’s active cooling cap technology that uses
continuous saline ﬂow to cool ﬁber tip. Cooling of the ﬁber tip could
protect laser ﬁber overheating and devitriﬁcation, and increase ﬁ-
ber longevity. Additionally, the metal-capped ﬁber tip also protects
the ﬁber from degradation due to contact with prostatic tissue.27
Limitations of this study are that this is a retrospective and
nonrandomized study with a limited case number and a short
follow-up period. Moreover, all the procedures were performed by
a single experienced surgeon using similar operative techniques. It
could not reﬂect different experiences of other surgeons, but could
provide decreased bias from different operators and more reliable
data. In addition, because more data were available in the early
period of HPS laser, we included 2008e2009 HPS group patients for
analysis instead of thosewho underwent HPS laser treatment in the
year right before XPS laser was introduced. Such a patient selection
may introduce some bias due to different periods of experience
with HPS laser.
5. Conclusion
From our preliminary results, the 180-W XPS system displays a
shorter lasing time, less laser ﬁber use, more volume reduction, and
a comparable safety proﬁle in comparison with the 120-W HPS
system for BPH treatment. Further studies with a longer follow-up
period and comparisonwith other treatment options arewarranted
to assess the sustainability of the 180-W XPS system.
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